Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting β2-agonists

This publication has 18 references indexed in Scilit:

• Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily
  Journal of Allergy and Clinical Immunology, 2003
• Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma
  Annals of Allergy, Asthma & Immunology, 2002
• Comparison of Fluticasone Propionate–Salmeterol Combination Therapy and Montelukast in Patients Who Are Symptomatic on Short-acting β₂-Agonists Alone
  American Journal of Respiratory and Critical Care Medicine, 2001
• Salmeterol/fluticasone propionate combination therapy 50/250 μ g twice daily is more effective than budesonide 800 μ g twice daily in treating moderate to severe asthma
  Respiratory Medicine, 2000
• Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma
  Annals of Allergy, Asthma & Immunology, 1999
• Ligand-independent Activation of the Glucocorticoid Receptor by β2-Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and Vascular Smooth Muscle Cells
  Journal of Biological Chemistry, 1999
• The complementary role of glucocorticosteroids and long‐acting β‐adrenergic agonists
  Allergy, 1998
• Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma
  New England Journal of Medicine, 1997
• Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.
  American Journal of Respiratory and Critical Care Medicine, 1996
• Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
  The Lancet, 1994